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Abstract
Background
In 2007, the Cameroon Baptist Convention Health Services (CBCHS) implemented a
screen-and-treat cervical cancer prevention program using visual inspection with acetic
acid enhanced by digital cervicography (VIA-DC).
Methods
We retrospectively analyzed 46,048 medical records of women who received care through
the CBCHSWomen’s Health Program from 2007 through 2014 to determine the prevalence
and predictors of positive VIA-DC, rates of same day treatment, and cohort prevalence of
invasive cervical cancer (ICC).
Results
Of the 44,979 women who were screened for cervical cancer, 9.0% were VIA-DC-positive,
66.8% were VIA-DC-negative, 22.0% were VIA-DC-inadequate (normal ectocervix, but por-
tions of the transformation zone were obscured), and 2.2% were VIA-DC-uncertain (cervical
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abnormalities confounding VIA-DC interpretation). Risk factors significantly associated with
VIA-DC-positive screen were HIV-positivity, young age at sexual debut, higher lifetime num-
ber of sexual partners, low education status and higher gravidity. In 2014, 31.1% of women
eligible for cryotherapy underwent same day treatment. Among the 32,788 women
screened from 2007 through 2013, 201 cases of ICC were identified corresponding to a
cohort prevalence of 613 per 100,000.
Conclusions
High rate of VIA-DC-positive screens suggests a significant burden of potential cervical can-
cer cases and highlights the need for expansion of cervical cancer screening and preven-
tion throughout the 10 regions of Cameroon. VIA-DC-inadequate rates were also high,
especially in older women, and additional screening methods are needed to confirm
whether these results are truly negative. In comparison to similar screening programs in
sub-Saharan Africa there was low utilization of same day cryotherapy treatment. Further
studies are required to characterize possible program specific barriers to treatment, for
example cultural demands, health system challenges and cost of procedure. The preva-
lence of ICC among women who presented for screening was high and requires further
investigation.
Introduction
Invasive cervical cancer (ICC) is the leading cause of cancer mortality among women in sub-
Saharan Africa (SSA) with approximately 99,000 new cases and 57,400 deaths in 2012 [1, 2].
The high burden of ICC in SSA is due to low awareness about screening, limited healthcare
infrastructure and a paucity of cost-effective screening programs [3]. In addition, the expand-
ing number of women living with human immunodeficiency virus (HIV) and human papillo-
mavirus (HPV) co-infection is thought to have had a significant impact on the increasing
number of ICC cases [4]. Approximately 70% of the 36.9 million people living with HIV glob-
ally are in SSA [5], and Cameroon has the highest HIV prevalence in West and Central Africa
[6]. Furthermore, owing to certain increased susceptibilities, women make up the majority of
the HIV seropositive population in Africa [7], and nearly 40% of HIV seropositive women
without visible cervical abnormalities test positive for HPV infection, thus increasing their risk
for developing cervical intraepithelial neoplasia (CIN) or ICC [8].
Despite their relative increased risk, less than 19% of women in developing countries have
been screened for CIN even once in their lifetime [9]. This is a missed opportunity as screening
a woman with visual inspection with acetic acid (VIA) just once between the ages of 30 and 49
has been shown to decrease her lifetime risk of developing ICC by 26% [10]. Many developing
countries report rates of VIA-positivity in order to reflect burden of pre-cancerous lesions [11–
26]; however, the data regarding VIA-positivity in Cameroon is limited. Only two small studies
have addressed this issue, and report VIA-positive rates of 12.9% and 21.7% [27, 28]. Addition-
ally, ICC is reported as the second leading cause of cancer mortality and incidence among
women in Cameroon by GLOBOCAN 2012 from the International Agency for Research on
Cancer (IARC) (17.5 deaths per 100,000 per year and 30.0 cases per 100,000 per year) [2].
However, this may be an underestimation due to the lack of specific country-level data on cer-
vical cancer screening and the absence of a national cancer registry [1, 9, 29]. The quality of
Cervical Cancer Screening in Cameroon
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data included in these worldwide analyses varies by country and in an evaluation of country-
specific GLOBOCAN 2012 data, Cameroon received a score of E6 on a scale of excellent (A1)
to poor (G6) [30]. As such there is a need for more data describing rates of VIA-positivity and
ICC in Cameroon.
Cervical cancer screening is not provided routinely in the public health system utilized by
the majority of the Cameroonian population [31]. Therefore there is an urgent need for large
scale, sustainable cervical cancer screening programs throughout the country. In 2007, the
Cameroon Baptist Convention Health Services (CBCHS), a faith-based healthcare organiza-
tion, founded the Women’s Health Program (WHP) and began to provide World Health Orga-
nization (WHO)-endorsed screen-and-treat cervical cancer screening using a fee-for-service
model [32]. Utilizing a clinical database of 44,979 women screened for cervical cancer by the
CBCHSWHP from 2007 through 2014, we (i) describe the prevalence and predictors of posi-
tive visual inspection with acetic acid enhanced by digital cervicography (VIA-DC) screen, (ii)
document rates of same day treatment in women with pre-cancerous lesions and (iii) describe
cohort prevalence of ICC in a large scale screening program in Cameroon.
Materials and Methods
Procedure
The Institutional Review Boards at University of Massachusetts Medical School (UMMS) and
Cameroon Baptist Convention Health Services approved this project. The informed consent
requirement was waived for this retrospective chart review. The patient records were de-identi-
fied and analyzed anonymously.
The WHP procedure for cervical cancer screening was modeled after the Cervical Cancer
Prevention Program in Zambia (CCPPZ), a regional leader in implementing screening pro-
grams based on VIA-DC [14]. This technique employs a commercial brand digital camera pro-
jecting magnified, real-time images of the cervix onto a television monitor visible to both
patient and provider. Permanent photographs of the cervix (cervicographs) are then stored to
assist with quality control and patient/provider education [33]. All screening done by WHP
was performed by nurse clinicians according to standard protocol as outlined by the IARC
[34]. The procedure began with examination of the external genitalia, followed by a sterile
speculum exam of the cervix and upper vagina. Diluted 3–5% acetic acid was then applied to
the cervix for 2 minutes, after which visual inspection was performed to assess for acetowhite
changes. Cervicographs were taken both before and after application of acetic acid. Following
VIA-DC, visual inspection with Lugol’s iodine (VILI-DC) was also performed and another cer-
vicograph was obtained. Results of VIA-DC and VILI-DC were classified as negative, positive,
uncertain or inadequate. Detection of a distinct opaque acetowhite lesion on the cervix was
considered VIA-DC-positive. Results classified as VIA-DC-uncertain included those with non-
neoplastic cervical abnormalities confounding VIA-DC interpretation such as cervicitis, severe
atrophic changes or difficult-to-diagnose abnormalities. Results classified as inadequate
included those where the visible ectocervix was negative for acetowhite changes, but the pro-
vider could not visualize the entire squamocolumnar junction (SCJ).
Women with VIA-DC-positive screens were considered eligible for cryotherapy treatment
if the cervical lesion met all of the following criteria outlined in WHO guidelines [32, 35]:
1. Complete visualization of transformation zone (TZ) and acetowhite lesion (AWL) margins
2. AWL occupies<75% of the TZ and can be covered by the cryoprobe
3. No suspicion of cancer
Cervical Cancer Screening in Cameroon
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4. No evidence of reproductive tract infection or pregnancy
With patient consent, cryotherapy eligible women were offered immediate treatment.
Women who did not receive same day cryotherapy were given appointments to follow up for
treatment. Clinicians had the option to use free text to record an explanation for lack of same
day treatment. Women with cryotherapy ineligible AWL were referred to CBCHS hospitals for
treatment with loop electrosurgical excision procedure (LEEP) if they met all of the following
criteria:
1. AWL extends into canal or covers>75% of TZ or cannot be covered by cryoprobe
2. No suspicion of cancer
3. No evidence of reproductive tract infection or pregnancy
Biopsies were taken in cases of uncertainty or for lesions that were suspicious for ICC.
Biopsy and LEEP specimens underwent histopathologic assessment by pathologists at Yaoundé
Gyneco-Obstetric and Pediatric Hospital or Buea Regional Hospital. The histology results were
reported according to the Richart CIN staging system [36]. Nurses communicated histopatho-
logic results to patients and helped to arrange appropriate follow-up treatment.
Cervical cancer screening was offered to women aged25 years and to women less than age
25, if they were HIV positive. Pregnant women were excluded.
The CBCHSWHP has minimal external funding and no governmental funding. Thus low
cost fees, stratified based on the financial status of the community being served, were charged
for screening and treatment in order to sustain the program. Often, women who could not
afford to pay were screened and treated at no charge or asked to pay later. The WHP offered
additional services including clinical breast exam, family planning and treatment of reproduc-
tive tract infection.
Setting
Screening was conducted at seven WHP sites in hospitals or health centers located in North
West, Littoral, Central and South West regions of Cameroon, encompassing urban (Mboppi
Baptist Hospital, Etoug-Ebe Baptist Hospital Yaounde, Nkwen Baptist Health Center), semi-
urban (Baptist Hospital Mutengene, Banso Baptist Hospital, Kumba Baptist Health Center),
and rural referral (Mbingo Baptist Hospital) areas. The catchment area was further broadened
through short-term outreach screening clinics.
Data Collection
Nurses or peer educators collected patient data using a structured, paper-based, clinical record.
All patient demographic, social, and medical history, including HIV-status, was self-reported.
For biopsy and LEEP specimens, a pathology request form was filled at the time of collection
and then the Richart CIN histopathologic diagnosis was recorded by a pathologist at the time
of reading [36]. All paper records were sent to the CBCHS Regional Training Center in Muten-
gene for entry into a centralized electronic database. Clinical data fromMarch 2007 through
December 2014 were securely transferred to UMMS Department of Quantitative Health Sci-
ences for analysis. Data on inadequate results was not available from 2007 through 2008,
because the WHP enrollment form used during those years did not contain an option to report
inadequate results. Data fromMarch 2007 through December 2013 did not include detailed
information regarding eligibility for same day treatment. In January 2014, the clinical record
forms were updated to capture this information. We performed a secondary analysis of data
from January 2014 to December 2014 in order to report same day cryotherapy rates.
Cervical Cancer Screening in Cameroon
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Histopathology data were only available for women screened from 2007 through 2013 and
were not linked to VIA-DC screening data due to inconsistencies in recording of unique
patient identifiers. Instances of duplicate patient identifiers were removed from the dataset.
Statistical Analysis
We obtained summary measures (median, proportions, inter-quartile range) for all character-
istics for the total sample as well as by VIA-DC status (positive, negative). Kappa statistic dem-
onstrated that there was a strong agreement between VIA-DC and VILI-DC (Κ = 0.927,
p 0.001); thus only VIA-DC outcomes were used for analysis. In order to identify factors
associated with VIA-DC-positive versus VIA-DC-negative screen, we obtained adjusted odds
ratios (AOR) and 95% confidence intervals (CI) from a multivariable logistic regression model
with an exchangeable correlation structure to account for the clustering of patients within sites.
The covariates included self-reported HIV status (positive, negative, unknown), age (18–29,
30–39, 40–49, 50+), years of education (<8, 8+), marital status (married, single, widowed/sepa-
rated/divorced), occupation (housewife, formal sector, informal sector, other), screening loca-
tion (urban, semi-urban, rural referral, mobile clinics), gravidity (0, 1–4, 5+), age at sexual
debut (<16, 16–20, 21+) and number of lifetime sexual partners (<2, 2–4, 5+). Two-sided
p<0.05 was considered to be significant for all tests. Due to low sample size, only descriptive
statistics regarding histologic grade of the tissue specimens are presented. ICC prevalence was
not calculated for women of unknown age because histopathology data and VIA-DC screening
data were not linked due to inconsistency in recording of unique patient identifiers. Cases
missing age/date of birth were not consistent between the two datasets. Statistical analysis was
conducted using SPSS Version 22.0.
Results
Prevalence of VIA-DC-positive screen
FromMarch 2007 through December 2014 a total of 46,048 women visited the WHP clinics
for health services, and 97.7% (n = 44,979) underwent VIA-DC screening (Fig 1). Demo-
graphic data is presented in Table 1. The overall VIA-DC-positive rate was 9.0%. The majority
of women who underwent cervical cancer screening were VIA-DC-negative (66.8%). A sub-
stantial minority (22.0%) screened VIA-DC-inadequate due to incomplete visualization of the
transformation zone; annual rates varied from 38.1% to 13.1%. The rate of VIA-DC-inadequate
results also varied by age, with women over age 50 having the highest rates of inadequate
screens (48.8%) (Table 2). An additional 2.2% of women screened VIA-DC-uncertain due to
concurrent reproductive tract infections, severe atrophic changes or difficult-to-diagnose
abnormalities that confounded VIA-DC interpretation.
Predictors of VIA-DC-positive screen
HIV-positive women were 1.36 (95%CI: 1.22–1.53) times more likely than HIV-negative
women to screen VIA-DC-positive (Table 3). Women with 8 or more years of education were
10% less likely to screen positive (OR: 0.90, 95% CI: 0.82–0.98) than those who were less edu-
cated. Higher gravidity and risk factors related to high-risk sexual behavior, including younger
age at sexual debut and increased number of lifetime sexual partners, were independently asso-
ciated with VIA-DC-positive screen after adjusting for other covariates. Age, marital status and
occupation were not associated with VIA-DC-positive screen.
Cervical Cancer Screening in Cameroon
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Treatment uptake
Women who screened VIA-DC-positive were offered same day cryotherapy, biopsy or referral
for LEEP depending upon the characteristics and severity of dysplasia of the observed lesion.
Data from 2007 through 2013 did not include detailed information regarding eligibility for
same day treatment, rates of uptake, or reasons for attrition. In 2014, the data collection form
was updated to document eligibility for cryotherapy based on the previously described WHO
guidelines. In 2014 alone, 12,191 women underwent VIA-DC screening, and 927 (7.6%)
screened VIA-DC-positive (Fig 1). Of these women, 705 (76.0%) were eligible for same day
cryotherapy, 219 (31.1%) underwent same day treatment, and 486 who did not receive same
day treatment were asked to return for follow up (Fig 1). Of the 486 women who did not
undergo same day treatment, 54 records (11.1%) included notation regarding reason for delay
in treatment. Of those records, 14.8% (n = 8) cited equipment failure (empty carbon dioxide
tank, cryotherapy probe out for repair), 25.9% (n = 14) cited desire to discuss treatment with
husband/family, 24.1% (n = 13) cited referral for LEEP due to co-morbid genital condyloma,
other complicating conditions or patient preference to wait until treatment of another condi-
tion was resolved, 33.3% (n = 18) cited deferment of cryotherapy until review of cervicographs
by a supervisor, and 1.9% (n = 1) cited inability to pay for procedure. Women who screened
VIA-DC-positive, but required LEEP (n = 134) or underwent biopsy due to suspicion for can-
cer (n = 88) were not eligible for same day treatment. The proportion of women who returned
for treatment as counseled is unknown.
Prevalence of invasive cervical cancer
FromMarch 2007 through December 2013, 32,788 women were screened with VIA-DC and
764 specimens were collected from women with VIA-DC-positive and -uncertain screens.
Among biopsy and LEEP specimens 14 (1.8%) were negative, 246 (32.2%) were CIN1, 177
(23.2%) were CIN2, 126 (16.5%) were CIN3/carcinoma-in-situ and 201 (26.3%) were ICC
(Table 4). Assuming that VIA-DC screening captured all ICC cases among women who visited
Fig 1. VIA-DC Screening and Treatment Data Flow Chart.
doi:10.1371/journal.pone.0157319.g001
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Table 1. Characteristics of Women Enrolled in CBCHSWHP Cervical Cancer Screening Program from
2007 to 2014.
Characteristic Data from 2007–2014
Age, median (IQR) 38 (30–47)
Education (years of school completed), n (%)
<8 23,546 (55.4)
8+ 18,974 (44.6)
Marital Status, n (%)
Married 29,698 (66.4)
Single (never married) 7,073 (15.8)
Widowed/Separated/Divorced 7,942 (17.8)
Occupation a, n (%)
Housewife 5,098 (11.8)
Formal Sector 6,031 (13.9)
Informal sector 27,528 (63.5)
Other 4,704 (10.8)
Screening Location, n (%)
Urban 10,567 (23.6)
Semi-Urban 10,470 (23.4)
Rural Referral 3,932 (8.8)
Mobile Clinics 19,831 (44.3)
Gravidity, n (%)
0 3,262 (7.4)
1–4 19,141 (43.2)
5+ 21,922 (49.5)
Age at Sexual Debut, n (%)
<16 7,621 (19.0)
16–20 27,425 (68.4)
21+ 5,066 (12.6)
Number of Sexual Partners (lifetime), n (%)
<2 12,445 (30.5)
2–4 19,707 (48.3)
5+ 8,623 (21.1)
VIA-DC, n (%)
VIA-DC-negative 30,049 (66.8)
VIA-DC-positive 4,042 (9.0)
VIA-DC-uncertain 1,011 (2.2)
VIA-DC-inadequate 9,877 (22.0)
Self reported HIV Status, n (%)
HIV-negative 29,475 (65.5)
HIV-positive 4,933 (11.0)
HIV-unknown 10,571 (23.5)
a Formal occupations: teacher, healthcare worker, secretary; Informal occupations: farmer, trader,
seamstress, domestic worker, hair dresser; Other occupations: sex worker, laborer, security ofﬁcer, military,
retired, etc.
doi:10.1371/journal.pone.0157319.t001
Cervical Cancer Screening in Cameroon
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Table 2. Age-specific VIA-DC Results.
Age Category, n (%) VIA-DC-negative VIA-DC-positive VIA-DC-Inadequate VIA-DC-Uncertain Total
18–29 8,138 (77.3) 1,090 (10.4) 1,111 (10.6) 184 (1.7) 10,523
30–39 10,225 (75.1) 1,434 (10.5) 1,669 (12.3) 292 (2.1) 13,620
40–49 7,181 (67.6) 913 (8.6) 2,295 (21.6) 240 (2.3) 10,629
50+ 3,987 (42.7) 537 (5.7) 4,561 (48.8) 253 (2.7) 9,338
Unknown 518 (59.6) 68 (7.8) 241 (27.7) 42 (4.8) 869
Total 30,049 (66.8) 4,042 (9.0) 9,877 (22.0) 1,011 (2.2) 44,979
doi:10.1371/journal.pone.0157319.t002
Table 3. Adjusted Odds Ratios and 95%Confidence Intervals for VIA-DC-positive Screen.
Variables VIA-DC-negative VIA-DC-positive AORa [95% CI] p-value
HIV Status, n (%) .001*
HIV-Negative 21,039 (70.0) 2,526 (62.5) 1
HIV-Positive 3,209 (10.7) 682 (16.9) 1.36 [1.22–1.53]
HIV-Status Unknown 5,801 (19.3) 834 (20.6) 1.18 [1.07–1.30]
Age, n (%) .216
29 8,138 (27.6) 1,090 (27.4) 1
30–39 10,225 (34.6) 1,434 (36.1) 0.99 [0.89–1.09]
40–49 7,181 (24.3) 913 (23.0) 0.91 [0.81–1.02]
50+ 3,987 (13.5) 537 (13.5) 0.89 [0.76–1.03]
Education, n (%) .020*
<8 14,874 (52.0) 2,080 (54.5) 1
8+ 13,739 (48.0) 1,740 (45.5) 0.90 [0.82–0.98]
Marital Status, n (%) .294
Married 20,768 (69.5) 2,615 (65.1) 1
Single (never married) 5,032 (16.8) 721 (17.9) 1.07 [0.95–1.19]
Widowed/Separated/Divorced 4,069 (13.6) 682 (17.0) 1.08 [0.96–1.20]
Occupation, n (%) .758
Housewife 3,569 (12.3) 450 (11.7) 1
Formal 4,307 (14.8) 511 (13.3) 1.00 [0.86–1.17]
Informal 17,715 (61.0) 2,436 (63.6) 1.04 [0.93–1.18]
Other 3,453 (11.9) 433 (11.3) 1.07 [0.91–1.26]
Age at Sexual Debut, n (%) .003*
<16 4,904 (18.4) 746 (21.2) 1
16–20 18,398 (69.1) 2,407 (68.4) 0.91 [0.83–0.99]
21+ 3,337 (12.5) 365 (10.4) 0.78 [0.68–0.90]
Number of Sexual Partners (lifetime), n (%) .001*
<2 7,808 (28.9) 848 (23.8) 1
2–4 13,457 (49.9) 1,800 (50.4) 1.15 [1.04–1.26]
5+ 5,720 (21.2) 921 (25.8) 1.33 [1.19–1.49]
Gravidity, n (%) .002*
0 1,797 (7.7) 151 (3.9) 1
1–4 11,156 (47.9) 2,397 (62.3) 1.32 [1.21–1.56]
5+ 10,333 (44.4) 1,299 (33.8) 1.23 [1.03–1.48]
aObtained from multivariable logistic regression model that included all variables in the table and adjusted for the clustering of patients within sites.
* Two-sided p<0.05 was considered to be signiﬁcant.
doi:10.1371/journal.pone.0157319.t003
Cervical Cancer Screening in Cameroon
PLOS ONE | DOI:10.1371/journal.pone.0157319 June 9, 2016 8 / 15
the WHP for screening from 2007 through 2013, the prevalence was 613 per 100,000 women
screened. The majority of ICC cases were in women greater than 50 years and the prevalence of
ICC among women screened also increased with age to a high of 1,717 per 100,000 in the over
50 age group (Table 4).
Discussion
The CBCHSWHP operates the largest cervical cancer screening program in Cameroon, a
country with the highest HIV prevalence in Western and Central Africa and where ICC is a
major contributor to cancer mortality [2, 6]. From 2007 through 2014, 44,979 women, nearly
all (97.7%) of those attending WHP clinics, were assessed through a fee-for-service visual
inspection screening program. Using this data we i) determined prevalence (9.0%) and predic-
tors of VIA-DC-positive screen (HIV-positivity, young age at sexual debut, higher number of
lifetime sexual partners, low education status, higher gravidity), ii) documented rates of same
day cryotherapy treatment in 2014 (31.1%), and iii) described the cohort ICC prevalence (613
per 100,000 women screened). Given the large number of women screened and the eight-year
data collection period, this analysis provides new and robust insights into the magnitude of cer-
vical pre-cancer and cancer in Cameroon.
Prevalence of VIA-DC-positive screen
The prevalence of VIA-DC-positive screen from 2007 through 2014 was 9.0%. These findings
are lower than or similar to two previous studies conducted in Cameroon. Specifically, one
study performed from 2001 to 2002 screened 4,813 women, comparing VIA and cytology as
screening methods for CIN/ICC, and reported a VIA-positive rate of 21.7%, higher than our
finding [28]. A possible explanation for inconsistency in rates between the studies is difference
in cohort risk for VIA-positive screen. The aforementioned study lacked risk factor characteri-
zation of the sample, for example they did not report HIV-status or lifetime number of sexual
partners. If their sample was at increased risk for VIA-positive screen we would expect a higher
VIA-positive rate. Another small screening program conducted from 2010 through 2012 evalu-
ated the effectiveness of HPV testing on self-obtained specimens followed by sequential VIA
testing and reported a VIA-positive rate of 12.9%, similar to our finding [27]. HIV status was
not reported; however, other VIA-positive risk factors were comparable between the studies.
Though lower than some previous studies, a rate of 9% VIA-DC-positive screen in a cohort of
44,979 women, stable over a period of eight years, suggests a significant burden of potential
Table 4. Frequency and Age-specific Ratesa of Histopathologic Results from Biopsy and LEEP specimens.
Age
Group
Total VIA-DC Screened
2007–13
Total
Specimens
Negative,
n (%)
CIN1,
n (%)
CIN2,
n (%)
CIN3,
n (%)
ICC,
n (%)
ICC
Prevalence
18–29 7,822 122 1 (0.80) 69 (56.6) 34 (27.9) 12 (9.8) 6 (4.9) 77
30–39 10,098 221 3 (1.4) 74 (33.5) 79 (35.7) 47 (21.3) 18 (8.1) 178
40–49 7,635 153 3 (2.0) 53 (34.6) 37 (24.2) 22 (14.4) 38 (24.8) 498
50+ 6,464 182 3 (1.6) 27 (14.8) 14 (7.7) 27 (14.8) 111
(61.0)
1,717
Unknown 769 86 4 (4.7) 23 (26.7) 13 (15.1) 18 (20.9) 28 (32.6) -
Total 32,788 764 14 (1.8) 246 (32.2) 177 (23.2) 126 (16.5) 201
(26.3)
613
aRates per 100,000 women screened
doi:10.1371/journal.pone.0157319.t004
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cervical cancer cases and highlights the need for expansion of cervical cancer screening and
prevention throughout the 10 regions of Cameroon.
The rate of VIA-DC-uncertain screens due to suspected cervicitis, severe atrophic changes
or difficult-to-diagnose abnormalities that confounded evaluation of the ectocervix was 2.2%
and is overall consistent with other reports in African countries, including Botswana [15],
Kenya [13], Côte d'Ivoire [12] and Zambia [37]. Other SSA studies did not report rates of VIA-
confounded results [19, 23].
The rate of VIA-DC-inadequate screens was high (22.0%). Although in these cases the ecto-
cervix was negative, the clinician was unable to visualize the entire SCJ. Most screening pro-
grams do not include a VIA-DC-inadequate category. For example the CCPPZ classification
includes only negative, positive, suspicious for cancer and VIA-uncertain/indeterminate which
is designated for those with non-neoplastic cervical abnormalities confounding VIA-DC inter-
pretation such as cervicitis or severe atrophic changes. Thus the CCPPZ classifies a negative
ectocervix with a non-visible SCJ as negative [37] whereas the WHP classifies it as VIA-DC-
inadequate.
The only study that included a category comparable to VIA-DC-inadequate was conducted
in Côte d'Ivoire and documented a rate of 2.3% [12]. The lower rate of inadequate screens in
the Côte d'Ivoire study is likely due to two factors. First, the women in the Côte d'Ivoire study
were younger (Median age = 36, IQR: 31–42 for Côte d'Ivoire vs Median age = 38, IQR: 30–47
for CBCHS) and thus less affected by the normal cervical aging process which includes squa-
mous epithelialization of the cervix that migrates the SCJ up into the endocervical canal [34].
Second, the Côte d'Ivoire study used VIA, not VIA-DC. VIA-DC incorporates a camera into
the screening process that, in some cases, complicates or precludes manipulation of the cervix
with a cotton tipped applicator to view the entire SCJ. Internal evaluation of the WHP screen-
ing process revealed that some portion of VIA-DC-inadequate results was due to lack of tech-
nical expertise among trained nurses at manipulating the cervix. For example, the annual
VIA-DC-inadequate rate peaked at 38.1% when senior staff were pulled away from screening
clinics to work on CBCHSWHP’s successful Gardasil HPV vaccination campaign [38]. Fol-
lowing staff training in techniques to expose the SCJ the VIA-DC-inadequate rate dropped to
13.1%, a rate similar to inadequate results documented in colposcopy, a technique that has sim-
ilar limitations [39].
In part due to the complications mentioned above, the WHO does not prioritize VIA
screening for women over age 50 [32]. In our program, however, a substantial number of
women over age 50 screened VIA-DC-positive (5.7%), and they accounted for 152 (30.2%) of
all 504 histopathologically confirmed CIN2+ cases. While the rates of VIA-DC positivity were
lower for the over 50 age group than any other age group, the prevalence of ICC was higher
than any other age group (1,717 per 100,000 women screened). Thus, screening in this age
group may provide meaningful clinical benefit, especially if cancer treatment is available.
Training clinicians on techniques to better visualize the SCJ in older patients and utilizing an
additional screening method such as HPV co-testing, when VIA-DC-inadequate results are
found are possible ways to decrease the number of VIA-DC-inadequate screens and better
inform treatment decisions.
Predictors of VIA-positive screen
Previous studies have shown that risk factors for VIA-positive screen in developing countries
include HIV-positive status [12, 13], low level of education, high number of lifetime sexual
partners, and younger age at sexual debut [37]. Our findings echo these results and indicate
that targeting screening toward women in Cameroon with these high risk characteristics may
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prove particularly beneficial. The association of age with VIA-positive screen varies; some stud-
ies have reported lower rates of VIA-positivity with increasing age [13, 37], others have
reported the opposite [17]. In our study, there was a non-significant trend towards lower rates
of VIA-positivity with increasing age. A large proportion (48.8%) of women aged over 50 were
classified as VIA-DC-inadequate rather than VIA-DC-negative due to incomplete visualization
of the SCJ and this may confound the association with age.
Treatment uptake
TheWHO screen-and-treat approach is recommended for cervical cancer prevention in devel-
oping countries due to its efficacy in decreasing cervical cancer related morbidity and mortality
[32, 40]. In addition to low cost, distinct advantages of this method include decreasing the
number of patients who are lost to follow up and minimizing cost incurred as a result of need-
ing to recall patients to the clinic. Despite offering same day treatment at all sites, the rate of
same day cryotherapy among women who screened VIA-DC-positive at the WHP was only
31.1% in 2014. Rates of same day cryotherapy have been reported to be higher in Zambia
(65%) [41], Ghana (70.2%) [11], and India (74.8%) [16]. These studies have reported barriers
to uptake of same day treatment including need to seek permission from spouse and equip-
ment failure or unavailability [11, 16]. Although we did not quantitatively measure explana-
tions for low utilization of same day treatment, retrospective review of staff notations in the
medical records revealed similar reasons. An additional barrier to same day treatment in the
WHP was cost. Although only a small percentage of staff notations reported cost as a barrier to
same day cryotherapy, nurses were not required to record a reason for non-treatment and con-
sequently this barrier is likely underreported. Informal discussion with WHP nurses regarding
reasons for same day cryotherapy refusal included cost as a major factor. Our evaluation high-
lights that a VIA-DC-positive screen does not result in reflexive uptake of same day cryother-
apy, especially in the face of health system challenges (equipment failure was reported by
14.8% while 33.3% reported need for review of cervicogragraphs by a supervisor who may not
have been immediately available), cultural demands (25.9% reported need to discuss treatment
with family members) and separate payment for the procedure. These factors undermine the
WHO-endorsed screen-and-treat approach in this setting and intimate that strengthening the
health system and restructuring the payment scheme might improve same day treatment of
VIA-DC-positive lesions.
Prevalence of invasive cervical cancer
The 5-year age-standardized prevalence of ICC in Cameroon, as estimated by GLOBOCAN
2012 analysis from the IARC, is 80.7 per 100,000 [2]. Due to the absence of a national cancer
registry and low quality of source data, current GLOBOCAN estimates may not accurately
reflect the ICC burden in Cameroon [29, 30]. Despite its limitations discussed below, in the
absence of a robust and rigorous dataset from which population-based ICC prevalence is calcu-
lated, data from a large-scale screening program such as the CBCHSWHP may provide addi-
tional insight into the burden of ICC in Cameroon.
The prevalence of ICC in women screened by the CBCHSWHP from 2007 through 2013
was 613 per 100,000. This result is not age-standardized and therefore not comparable with
population level data from GLOBOCAN. Nevertheless, the cohort specific ICC prevalence is
high. This is likely due in part to selection bias; women who self-presented or who were
referred to cervical cancer screening were more likely to have gynecologic symptoms or risk
factors for cervical cancer and thus do not represent the general population. In contrast, some
women who presented for VIA-DC screening and had lesions eligible for LEEP or biopsy did
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not receive the recommended procedure and therefore we do not know their true cervical can-
cer status. Our analysis assumes that these women are cancer-free, but some percentage of
these women may have had ICC. In this respect, the cohort prevalence of ICC reported in this
manuscript may underestimate the true prevalence of ICC in Cameroon.
Though high, the WHP prevalence of ICC was lower than that reported by the CCPPZ (700
per 100,000). This may be due in part to the difference in self reported HIV prevalence between
the two screened groups (11% HIV-positive in Cameroon vs 28% in Zambia) [41], different
prevalence of HIV/AIDS nationally (4.5% vs. 12.7% in 2012) [6] and different rates of male cir-
cumcision (94% vs. 21.6%) [42, 43] in Cameroon vs. Zambia as it has been shown that
HIV-HPV co-infection may play a synergistic role in development of cervical cancer [44] and
that male circumcision reduces the risk of HPV infection substantially [45, 46].
The prevalence of ICC was associated with age, peaking in women aged over 50. This find-
ing underscores the need for data regarding outcomes of treatment in women diagnosed with
ICC in resource poor settings in order to determine whether screening women aged 50 and
over is worthwhile.
Limitations
This analysis was a retrospective evaluation of a large-scale, grassroots, fee-for-service cervical
cancer screening program. Although this serves as a strength because it provides striking
insight into the realities of implementing a nearly self-sustaining program that did not rely on
short-term grant funding or expert oversight from a research team, there are limitations that
should be addressed to improve the quality of care. Some VIA-DC result categories changed
over time and in some cases were not comparable to categories in other studies. The high rate
of VIA-DC-inadequate results was in part dependent upon clinician expertise in VIA-DC tech-
nique. The HIV status of our patient population was self-reported. The data available regarding
treatment uptake is limited. Outcome of treatment decision (same day cryotherapy versus
referral) was systematically documented beginning in 2014, but reasons for treatment choice
were not systematically reported, leaving the question of specific barriers to treatment answer-
able only by anecdotal evidence per nurse clinician notes and informal discussion with WHP
staff. Data regarding follow-up treatment of cryotherapy eligible lesions was also not available,
precluding calculation of attrition rate among women referred for treatment at a later date.
At the time of data analysis, histopathology data was available only for women screened
from 2007 through 2013. We believe this delay is an honest reflection of the logistical difficulty
of pathologic diagnosis, dissemination of findings and upkeep of an electronic database in this
low-resource setting. Since ICC prevalence was calculated from women who self-presented for
screening or were referred by other providers, selection bias may have caused over-estimation
of the true prevalence. Additionally, removal of cases due to instances of duplicate patient iden-
tifiers and lack of pathology specimens on VIA-DC-positive and -uncertain women who did
not consent to biopsy or LEEP and were thus lost to follow-up may have caused under-estima-
tion of the true ICC prevalence.
Conclusion
The high rate of VIA-DC-positive results in Cameroon suggests a significant impending bur-
den of ICC cases. The rate of VIA-DC-inadequate (normal ectocervix, but portions of the
transformation zone were obscured) screens was high, especially in women aged 50 and over.
Training clinicians on techniques to better visualize the SCJ and adding an additional screening
method to the protocol in cases of VIA-DC-inadequate results are possible ways to confirm
whether these cases are truly negative. In comparison to similar screening programs in SSA, we
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report low utilization of same day cryotherapy treatment. Further studies are required to char-
acterize possible program specific barriers to treatment, for example cultural demands, health
system challenges and cost of procedure. The prevalence of ICC among women who presented
for screening was high and requires further investigation.
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